TKI258_FGFR_INHIBITOR_TREATMENT
Ontology highlight
ABSTRACT: New targets and drugs for treatment of breast cancer are needed. We tested the effects of the TKI258 (Novartis) FGFR-inhibitor on tumor formation in mice. 4T1 mouse cell line, which had been derived from BALB/c mice, was injected into tail veins of BALB/c mice (syngraft model). Seven days later, mice were treated with 0, 15 or 40 milligram per kilogram (dose) TKI258 inhibitor (compound). Tumors were resected after different time points (time) and effects of drug treatment on global gene expression was monitored.
ORGANISM(S): Mus musculus
SUBMITTER: Stefan Wiemann
PROVIDER: E-MTAB-1260 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA